Skip to main
KTTA

KTTA Stock Forecast & Price Target

KTTA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pasithea Therapeutics is well-positioned for success with strong potential for its drug candidates, particularly PAS-004 which may have broad utility beyond its initial target indications, and a favorable outlook for continued growth in the biotechnology sector. The company's solid balance sheet and progress in clinical trials make it a promising investment opportunity, with a promising Phase 1/1b study ongoing and expected data in the first quarter of 2026.

Bears say

Pasithea Therapeutics is a biotechnology company focused on developing treatments for CNS disorders and other diseases by leveraging their expertise in neuroscience, translational medicine, and drug development. Their current pipeline consists of three programs, with PAS-004 being their most promising project for treating RAS/RAF/NF1 mutated advanced solid tumors. However, there are potential risks associated with this program, as it is still in the early stages of clinical development and the company is being conservative in their market model approach, potentially limiting its potential upside. Additionally, there is strong competition in the MEK inhibitor market, with NFX-179 showing promising results for treating cutaneous NF1, potentially hindering Pasithea's market share in this area.

KTTA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pasithea Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pasithea Therapeutics Corp (KTTA) Forecast

Analysts have given KTTA a Strong Buy based on their latest research and market trends.

According to 1 analysts, KTTA has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pasithea Therapeutics Corp (KTTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.